Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an announcement.
Neuren Pharmaceuticals Limited has released its Annual Report for 2024, highlighting its commitment to improving the lives of individuals with neurodevelopmental disabilities. The report includes an operating review, financial statements, and insights into the company’s environmental, social, and governance practices, reflecting its strategic focus and operational progress.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is a company focused on developing new therapies for neurodevelopmental disorders that arise in early childhood, characterized by impaired brain cell connections and signaling. The company is incorporated in New Zealand, based in Melbourne, Australia, and listed on the ASX under the code NEU.
YTD Price Performance: -11.60%
Average Trading Volume: 781
Technical Sentiment Signal: Buy
Current Market Cap: $970.1M
For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.